FineImmu

About FineImmu

Guangzhou FineImmune Biotechnology Co., Ltd., also known as Fanen Biotechnology, is a clinical-stage biopharmaceutical company established in 2016, focusing on the development of immunotherapies for solid tumors. The company was founded by a team led by Dr. Penghui Zhou, a scholar who returned to China after his time at Harvard University. Dr. Zhou, who serves as the Chief Technology Officer, and his team bring nearly two decades of experience in tumor immunotherapy research and development, including postdoctoral work at Harvard Medical School.

FineImmune operates primarily in the challenging field of solid tumor cell therapy, a market segment with significant unmet needs compared to hematological malignancies. The company's business model centers on the research, development, and eventual commercialization of advanced T-cell therapies and related diagnostic tools. Its clients are primarily hospitals and cancer treatment centers. To support its operations, the company has established a 1600-2000 square meter R&D laboratory and a GMP-compliant production workshop for cell therapy products in Guangzhou Science City. FineImmune has successfully raised capital, including a notable Later Stage VC funding round in August 2022, attracting investors such as Panacea Venture and Holley Group.

The company's product pipeline is built upon several proprietary technology platforms designed to overcome key bottlenecks in the tumor microenvironment. These platforms include GSOP for T-cell engineering, HAP for TCR identification, and CMP for personalized TCR-T cell production. FineImmune is developing a diversified portfolio of therapies, including personalized TCR-T (T-cell receptor), CAR-T (Chimeric Antigen Receptor), TAL (Tumor-Associated Lymphocyte), and TIL (Tumor Infiltrating Lymphocyte) products. A key offering is a personalized neoantigen-specific TCR-T cell therapy, which has entered Phase I clinical trials. Another product, FIT-003, which utilizes tumor-associated lymph node T cells, is also in Phase I trials for treating metastatic solid tumors. In a significant strategic move, FineImmune entered into a collaboration with Biocytogen in September 2022 to co-develop cell-based therapeutic drugs against intracellular tumor-associated antigens, combining Biocytogen's antibody discovery platform with FineImmune's cell therapy expertise.